BIAFWHIGH SIGNALFINANCIAL10-K

BIAFW executed a major capital raise that dramatically improved its balance sheet while burning significantly more cash and posting wider losses.

The company raised substantial capital (cash increased 483% to $6.4M) which provides crucial runway for operations, but this came at the cost of significant dilution as evidenced by the equity increase. The widening net loss of $14.9M versus $9.0M prior year, combined with deteriorating operating cash flow burn, indicates the company is still far from profitability despite having a stronger balance sheet.

Comparing 2026-03-16 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

BIAFW's financial profile shows a tale of two stories - a dramatically strengthened balance sheet through capital raising (cash up 483%, total assets up 68%) but significantly deteriorating operational performance with net losses widening 65% to $14.9M and operating cash burn increasing 28% to $9.3M. The massive reduction in interest expense (down 98.5%) suggests debt restructuring or conversion, likely part of the capital raising process. While the company now has substantially more financial resources to fund operations, the accelerating cash burn and widening losses signal investors should closely monitor how quickly this new capital gets consumed.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+483.5%
$1.1M$6.4M

Cash position surged 483.5% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+180.7%
$2.7M$7.6M

Current assets grew 180.7% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+179.7%
$2.6M$7.3M

Equity base grew 179.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
-98.5%
$2.5M$37K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Inventory
Balance Sheet
+94%
$28K$54K

Inventory surged 94% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Assets
Balance Sheet
+68.3%
$6.5M$11.0M

Asset base grew 68.3% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
-64.9%
-$9.0M-$14.9M

Net income declined 64.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-28.4%
-$7.3M-$9.3M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
-23.4%
$79K$61K

Capex reduced 23.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-18.1%
-$9.0M-$10.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-31
ADDED
We are unable to precisely estimate when we will begin to generate significant profit from Precision Pathology Laboratory Services ( PPLS ).
Risks Related to Development and Commercialization of Our Diagnostic Tests Delays or difficulties in the enrollment of patients in our clinical trials could delay greater adoption by physicians of our commercial test.
If our tests do not perform as expected, our operating results, reputation, and business will suffer.
We are currently dependent upon our subsidiary, PPLS, to offer and perform CyPath Lung.
5 Risks Related to the Operation of Our Commercial Laboratory Accredited by the College of American Pathologists ( CAP ) and the U.S.
+7 more — sign up free →
REMOVED
Our limited operating history makes it difficult to evaluate our business and future prospects.
We are unable to precisely estimate when we will begin to generate significant profit from Precision Pathology Laboratory Services (PPLS).
Food and Drug Administration ( FDA ) clearance for CyPath Lung as an in vitro diagnostic, the FDA could impose greater regulatory burdens on laboratory developed tests ( LDTs ).
Delays or difficulties in the enrollment of patients could delay or prevent regulatory approvals.
Risks Related to Our Diagnostic Tests If our tests do not perform as expected, our operating results, reputation, and business will suffer.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →